WO2003104479A3 - IDENTIFICATION OF MITOSIS INHIBITORS - Google Patents

IDENTIFICATION OF MITOSIS INHIBITORS Download PDF

Info

Publication number
WO2003104479A3
WO2003104479A3 PCT/US2003/019743 US0319743W WO03104479A3 WO 2003104479 A3 WO2003104479 A3 WO 2003104479A3 US 0319743 W US0319743 W US 0319743W WO 03104479 A3 WO03104479 A3 WO 03104479A3
Authority
WO
WIPO (PCT)
Prior art keywords
identification
mitosis inhibitors
mitosis
inhibitors
nima
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/019743
Other languages
French (fr)
Other versions
WO2003104479A2 (en
Inventor
Amoros Joan Roig
Christopher Belham
Joseph Avruch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to AU2003253678A priority Critical patent/AU2003253678A1/en
Priority to US10/517,622 priority patent/US20060052582A1/en
Priority to JP2004511538A priority patent/JP2006512048A/en
Priority to EP03757508A priority patent/EP1554578A2/en
Publication of WO2003104479A2 publication Critical patent/WO2003104479A2/en
Publication of WO2003104479A3 publication Critical patent/WO2003104479A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés et des compositions d'utilisation de kinases du type NIMA pour identifier des composés antimitotiques et pour diagnostiquer le cancer.The invention relates to methods and compositions for using NIMA-like kinases to identify antimitotic compounds and to diagnose cancer.

PCT/US2003/019743 2002-06-11 2003-06-11 Identification of inhibitors of mitosis Ceased WO2003104479A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003253678A AU2003253678A1 (en) 2002-06-11 2003-06-11 Identification of inhibitors of mitosis
US10/517,622 US20060052582A1 (en) 2002-06-11 2003-06-11 Identification of inhibitors of mitosis
JP2004511538A JP2006512048A (en) 2002-06-11 2003-06-11 Identification of inhibitors of mitosis
EP03757508A EP1554578A2 (en) 2002-06-11 2003-06-11 Identification of inhibitors of mitosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38781002P 2002-06-11 2002-06-11
US60/387,810 2002-06-11

Publications (2)

Publication Number Publication Date
WO2003104479A2 WO2003104479A2 (en) 2003-12-18
WO2003104479A3 true WO2003104479A3 (en) 2004-09-23

Family

ID=29736369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/019743 Ceased WO2003104479A2 (en) 2002-06-11 2003-06-11 Identification of inhibitors of mitosis

Country Status (5)

Country Link
US (1) US20060052582A1 (en)
EP (1) EP1554578A2 (en)
JP (1) JP2006512048A (en)
AU (1) AU2003253678A1 (en)
WO (1) WO2003104479A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008078085A1 (en) * 2006-12-22 2008-07-03 Astrazeneca Ab Method
FR2926367B1 (en) * 2008-01-10 2013-01-04 Novaleads FLUORIMETRIC METHOD FOR EVALUATING THE INFLUENCE OF A CONDITION ON A BIOLOGICAL SAMPLE AND ITS APPLICATIONS
JPWO2018066039A1 (en) * 2016-10-03 2019-06-24 株式会社ニコン Analysis device, analysis method, and program

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047750A1 (en) * 1996-06-10 1997-12-18 Immunex Corporation IL-1/TNF-α-ACTIVATED KINASE (ITAK), AND METHODS OF MAKING AND USING THE SAME
WO1999066051A2 (en) * 1998-06-16 1999-12-23 Sugen, Inc. Nek-related and bub1-related protein kinases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047750A1 (en) * 1996-06-10 1997-12-18 Immunex Corporation IL-1/TNF-α-ACTIVATED KINASE (ITAK), AND METHODS OF MAKING AND USING THE SAME
WO1999066051A2 (en) * 1998-06-16 1999-12-23 Sugen, Inc. Nek-related and bub1-related protein kinases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ [online] 18 December 1997 (1997-12-18), SIMS J.E. ET AL: "Nucleic acid encoding interleuking-1/tumour necrosis factor activated kinase - used to identify specific antagonists for treatment of cytokine-meddiated inflammation", XP002981012, Database accession no. AAW40309 *
ROIG J. ET AL: "Nercc1, a mammalian NIMA-family kinase, binds the Ran GTPase and regulates mitotic progression", GENES & DEVELOPEMENT, vol. 16, July 2002 (2002-07-01), pages 1640 - 1658, XP002981013 *

Also Published As

Publication number Publication date
US20060052582A1 (en) 2006-03-09
JP2006512048A (en) 2006-04-13
AU2003253678A8 (en) 2003-12-22
AU2003253678A1 (en) 2003-12-22
EP1554578A2 (en) 2005-07-20
WO2003104479A2 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
WO2003105840A3 (en) SPHINGOSINE KINASE INHIBITORS
MA62912A1 (en) INHIBITION OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1)
ID29552A (en) TRIAZOLA COMPOUNDS AND ITS USE
EA199900373A2 (en) PHARMACEUTICAL COMPOSITIONS
EA200500442A1 (en) COMPOSITIONS AND KITS TO REMOVE AN IRRITABLE COMPOUNDS FROM BODY SURFACES
NZ506329A (en) Inhibitors of phospholipase enzymes
TNSN99006A1 (en) 4- (2-CETO-1-BENZIMIDAZOLINYL) NOVEL PIPERIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MA31606B1 (en) ANTI-CD 79B IMMUNOCONJUGATED ANTIBODIES AND METHODS OF USE
BR0317715A (en) Compositions and processes of use of collajolie
CY1115124T1 (en) Substituted 3-Cyanoquinolines as Suspensions of Protein Tyrosine Kinases
AU2002359522A8 (en) Compositions and methods of selective nucleic acid isolation
EA200501274A1 (en) PYRAZOLES AND METHODS FOR THEIR PRODUCTION AND APPLICATION
MA29154B1 (en) GEMCITABINE AMIDE PROMEDICAMENT, COMPOSITIONS AND USES THEREOF
MXPA04003886A (en) Thiopene- amd thiazolesulfonamides as antineoplastic agents.
BRPI0606379A2 (en) triazolphtalazine
MXPA04004939A (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them.
IS5553A (en) Quinolone as Serine Protein Chaperone Inhibitors
TW200628534A (en) Retention and drainage aids
MXPA04003755A (en) Stents.
ATE443044T1 (en) TACE INHIBITORS
PL1831209T3 (en) Cdc25 phosphatase inhibitors
MY128164A (en) Compounds
MXPA02008453A (en) Methods for selectively modulating survivin apoptosis pathways.
BG105539A (en) ELETRIPTAN HYDROBROMIDE MONOHYDRATE
SI1377574T1 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004511538

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2006052582

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10517622

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003757508

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003757508

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10517622

Country of ref document: US